Krystal Biotech, Inc. is a clinical-stage gene therapy company. The Company is using its proprietary Skin TARgeted Delivery (STAR-D) platform to develop treatments for skin diseases. The CompanyÔÇÖs products are directed to the treatment of monogenic and congenital skin diseases, including dystrophic epidermolysis bullosa (DEB) and autosomal recessive congenital ichthyosis (ARCI). DEB is an incurable, often fatal skin blistering condition caused by mutations in the gene encoding type VII collagen (COL7), a protein that provides critical structural adhesion between skin layers in a normal individual. Beremagene geperpavec (B-VEC)a replication-defective, non-integrating HSV-1 that is based on the Company's viral gene therapy platform, is the CompanyÔÇÖs product candidate being evaluated in humans and is the subject of a planned phase III clinical trial.
Number of employees : 75 people.
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|Redmile Group LLC ||2,060,132||
|Krish S. Krishnan ||1,886,462||
|Suma M. Krishnan ||1,836,064||
|Lord, Abbett & Co. LLC ||1,385,643||
|Fidelity Management & Research Co. LLC ||1,341,897||
|OrbiMed Advisors LLC ||994,808||
|Sun Pharmaceutical Industries Limited ||914,107||
|Frazier Management LLC ||895,000||
|The Vanguard Group, Inc. ||783,890||
|Credit Suisse Securities (USA) LLC (Broker) ||779,400||
|Company contact information|
Sector Bio Therapeutic Drugs
Connections : Krystal Biotech, Inc.